Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience, focused on women’s health, announced CEO Sabrina Martucci Johnson's participation in two virtual conferences on September 14 and 15, 2020. She will join the Women’s Health Innovation Summit's expert panel for women-centric clinical research and a CEO leadership panel, with both discussions available on-demand. Additionally, Johnson will present a company update at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:00 PM EDT. Live webcasts and an archive will be accessible through the company's website.
Daré Bioscience (NASDAQ: DARE) has formed a strategic partnership with Avomeen to enhance the development of its women’s health product pipeline. This agreement will allow Avomeen to provide tailored product development laboratory services for the next three years, prioritizing projects like Ovaprene®, a hormone-free contraceptive. The collaboration aims to leverage Avomeen’s scientific expertise to improve efficiency and reduce research costs. Both companies believe this partnership will facilitate faster market introductions for innovative products targeting unmet needs in women's health.
Daré Bioscience (NASDAQ: DARE) announced that Sabrina Martucci Johnson, President and CEO, will join a panel at Maxim Group's M-Vest Virtual Conference on August 13, 2020, at 10:00 a.m. ET. The discussion, moderated by Jason McCarthy, PhD, focuses on innovations in women's health. Daré is dedicated to advancing women's health through innovative product development, with a clinical-stage portfolio that includes Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1. For event registration and details, visit https://bit.ly/2DlgeRW.
Daré Bioscience (NASDAQ: DARE) has initiated a Phase 1 clinical trial for DARE-HRT1, aimed at delivering bio-identical hormones over 28 days to treat menopausal symptoms and prevent bone loss. This IVR product could be the first FDA-approved option following NAMS guidelines. The study will assess pharmacokinetics and safety in post-menopausal women. Conducted in Australia, the trial also allows for potential cash credits from the R&D tax incentive. The technology promises to enhance convenience and effectiveness in hormone therapy.
Daré Bioscience (NASDAQ: DARE) has published a literature review in Biology of Reproduction, highlighting positive results from a postcoital test (PCT) study of their hormone-free contraceptive, Ovaprene. The review concludes that PCT is a strong predictor of contraceptive effectiveness. Furthermore, if Ovaprene's clinical trial success aligns with previous studies, it may achieve contraceptive effectiveness rates of 86-91% comparable to traditional methods. Daré has an exclusive licensing agreement with Bayer for U.S. commercialization, which could yield up to $310 million in milestone payments and royalties.
Daré Bioscience (NASDAQ: DARE) announced it received an additional $1.5 million grant from the Bill & Melinda Gates Foundation, enhancing its development of the DARE-LARC1 contraceptive program. This funding is part of a previous $18 million commitment from the foundation, with an expectation of another $1 million by year-end. DARE-LARC1 aims to deliver precise drug doses from an implant, allowing user-controlled release. The company is focused on advancing innovative women's health products, including several clinical candidates.
Daré Bioscience (NASDAQ: DARE) announced its participation in the BIO Digital International Convention from June 8-12, 2020. CEO Sabrina Martucci Johnson will join a panel titled Redefining BioPharma in a Female-Forward World and deliver a company presentation. Both sessions will be available on-demand for registered attendees. Daré focuses on innovative women's health solutions including contraceptives and treatments for sexual health and bacterial vaginosis. The company aims to enhance treatment options and improve health outcomes for women.
Daré Bioscience (NASDAQ: DARE) has partnered with Health Decisions to enhance its clinical development for women's health products. This exclusive agreement assigns Health Decisions to provide CRO services in the U.S. for three years, focusing on Daré's reproductive health assets, including its pivotal Ovaprene® study and the DARE-BV1 Phase 3 study in bacterial vaginosis. The collaboration aims to leverage Health Decisions’ expertise and reduce clinical development costs. The partnership could expedite the advancement of innovative treatments in contraception, fertility, and gynecological disorders.
Daré Bioscience (NASDAQ: DARE) announced a conference call on May 14, 2020, at 4:30 p.m. ET to discuss Q1 2020 financial results and provide a company update. Investors can join the call by dialing (844) 831-3031 or through a live webcast available on their website. The company focuses on women's health innovations, with products in development including Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1. The call will be accessible for replay until May 21, 2020.
Summary not available.